KIT and chronic myelogenous leukemia, BCR-ABL1 positive: In patients with CML, during the first 6–12 months of TKI treatment, the white blood cell counts, including the lymphocyte counts, may vary considerably due to the off-target inhibition of the stem cell factor c-kit.